Technical Analysis for SPPI - Spectrum Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade B 19.7 -0.61% -0.12
SPPI closed down 0.61 percent on Wednesday, November 22, 2017, on 41 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical SPPI trend table...

Date Alert Name Type % Chg
Nov 22 NR7 Range Contraction 0.00%
Nov 21 Upper Bollinger Band Walk Other -0.61%
Nov 20 Bollinger Band Squeeze Range Contraction 3.03%
Nov 17 Bearish Engulfing Bearish 1.03%
Nov 17 Bollinger Band Squeeze Range Contraction 1.03%
Nov 16 New 52 Week Closing High Bullish -4.97%
Nov 16 Bollinger Band Squeeze Range Contraction -4.97%
Nov 15 Bollinger Band Squeeze Range Contraction 0.20%
Nov 14 Stochastic Buy Signal Bullish 4.79%
Nov 14 Bollinger Band Squeeze Range Contraction 4.79%

Older signals for SPPI ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

Profile
Spectrum Pharmaceuticals, Inc., a biotechnology company, engages in acquiring, developing, and commercializing prescription drug products primarily in the areas of hematology and oncology. The company's oncology products include FUSILEV for patients with osteosarcoma after high-dose methotrexate therapy, and to diminish toxicity and counteract the effects of impaired methotrexate elimination or inadvertent overdose of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma; and ZEVALIN, a prescribed form of cancer therapy which combines a source of radiation with an antibody. It also develops apaziquone that is under Phase III clinical trial for non-muscle invasive bladder cancer; and belinostat, which is under Phase II registrational trial for the various hematological and solid tumors. In addition, the company develops ozarelix that is under randomized phase II clinical trial in prostate cancer patients; ortataxel, which has completed Phase II studies in solid tumor patients; lucanthone, an orally administered small-molecule that has completed preclinical tests; SPI-1620, which has completed Phase I study is a peptide agonist of endothelin B receptors; RenaZorb, a second-generation lanthanum-based nanoparticle phosphate binding agent; and SPI-2012, a drug for the treatment of chemotherapy induced neutropenia. It has strategic collaborations with Allergan, Inc., Nippon Kayaku Co. Ltd., and Handok Pharmaceuticals Co. Ltd. for the development and commercialization of apaziquone; and TopoTarget A/S for the development and commercialization of belinostat. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is based in Henderson, Nevada.
Is SPPI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 21.95
52 Week Low 3.85
Average Volume 2,141,101
200-Day Moving Average 9.3864
50-Day Moving Average 15.9848
20-Day Moving Average 19.2735
10-Day Moving Average 19.285
Average True Range 1.0331
ADX 39.22
+DI 31.81
-DI 14.66
Chandelier Exit (Long, 3 ATRs ) 17.9007
Chandelier Exit (Short, 3 ATRs ) 21.1693
Upper Bollinger Band 20.3275
Lower Bollinger Band 18.2195
Percent B (%b) 0.7
BandWidth 10.937297
MACD Line 0.9291
MACD Signal Line 1.111
MACD Histogram -0.1819
Fundamentals Value
Market Cap 1.55 Billion
Num Shares 78.8 Million
EPS -1.00
Price-to-Earnings (P/E) Ratio -19.70
Price-to-Sales 11.56
Price-to-Book 7.68
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 20.60
Resistance 3 (R3) 20.61 20.33 20.45
Resistance 2 (R2) 20.33 20.10 20.32 20.40
Resistance 1 (R1) 20.01 19.96 19.87 20.00 20.35
Pivot Point 19.73 19.73 19.66 19.72 19.73
Support 1 (S1) 19.41 19.50 19.27 19.40 19.05
Support 2 (S2) 19.13 19.36 19.12 19.00
Support 3 (S3) 18.81 19.13 18.95
Support 4 (S4) 18.80